secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073689
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q4: cash $205M, OpEx down 30%, FT819 outpatient treatment milestone
--------------------------------------------------------------------------------

- Cash and investments $205.1M as of Dec 31, 2025; operating runway through year-end 2027.
- Q4 revenue $1.4M from Ono collaboration; total operating expenses $36.1M (R&D $25.4M, G&A $10.7M).
- FT819 off-the-shelf CAR T: 15 SLE, 4 SSc, 1 IIM patients treated; outpatient same-day discharge achieved.
- FT836 (Sword & Shield) in CRC: first patient shows >50% CEA reduction and tumor shrinkage at DL1 without conditioning chemo.
- Operating expenses reduced 30% in 2025 vs 2024; common shares 115.4M, pre-funded warrants 3.9M, preferred 2.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312526073689/0001193125-26-073689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312526073689/fate-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer